Biohaven Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
$3.9B
Website

Study of BHV-4157 in Alzheimer's Disease

First Posted Date
2018-07-30
Last Posted Date
2023-12-06
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
350
Registration Number
NCT03605667
Locations
🇺🇸

Northern Light Acadia Hospital, Bangor, Maine, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Brain Matters Research, Delray Beach, Florida, United States

and more 41 locations

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

First Posted Date
2018-05-09
Last Posted Date
2022-10-06
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
22
Registration Number
NCT03520517
Locations
🇺🇸

Wesley Neurology Clinic, Cordova, Tennessee, United States

🇺🇸

Holy Cross Neuroscience Research Institute, Fort Lauderdale, Florida, United States

🇺🇸

Texas Neurology, Dallas, Texas, United States

and more 2 locations

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2017-10-02
Last Posted Date
2023-09-08
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
426
Registration Number
NCT03299166
Locations
🇺🇸

CalNeuro Research Group, Los Angeles, California, United States

🇺🇸

Desert Valley Research, Rancho Mirage, California, United States

🇺🇸

Gulfcoast Clinical Research Center, Fort Myers, Florida, United States

and more 52 locations

Trial in Adult Subjects With Spinocerebellar Ataxia

First Posted Date
2016-11-10
Last Posted Date
2024-10-16
Lead Sponsor
Biohaven Pharmaceuticals, Inc.
Target Recruit Count
141
Registration Number
NCT02960893
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 15 locations
© Copyright 2024. All Rights Reserved by MedPath